| rosiglitazone / Generic mfg. |
ChiCTR-TRC-09000670: Clinical and Metabolic Effects of Rosiglitazone on Women with Polycystic Ovarian Syndrome |
|
|
| Completed | N/A | 70 | | Rosiglitazone 4mg B.D. (8mg per day) 12 months versus Placebo 1 tab B.D. | N/A; Level of the institution：, 1) Lee Hysan Foundation Research Grant and Endowment Fund Research Grant 2003/2004 (United College, CUHK) 2) RGC Research Grant Direct Allocation 2004 (CUHK) | Polycystic Ovarian Syndrome | | | | |
| Completed | N/A | 2832 | | Intensive control of blood glucose and pressure ;Intensive control of blood glucose, lipids and blood pressure ;intensive control of blood glucose (with rosiglitazone sodium single or combined treatment), lipids and blood pressure ;Intensive control of blood glucose, lipids and blood pressure, combined the treatment of compound Danshen Di Wan ;(IMT>1.3mm) intensive control of blood glucose, lipids and blood pressure ;control group (IMT<1.2mm), random treatment in outpatient department ;control group (IMT without limit), random treatment in outpatient department | Beijing Hospital of China Ministry of Health; Ministry of Science and Technology, the 11th five-year science and technology support project | type 2 diabetes | | | | |
ChiCTR-TRC-06000683: A Randomized, Double Blind, Placebo Controlled Trial on the Effect of Rosiglitazone in Reversion of Newly Diagnosed Type 2 Diabetes to Non-Diabetic Status |
|
|
| Completed | N/A | 80 | | Primary intervention: Rosiglitasone or Placebo for 52 weeks. Secondary intervention: Standard advice on lifestyle modification for 52 weeks versus placebo | Dr Francis C.C. Chow; Dr Wing Bun Chan Dr Wing Yee So Dr Ronald C.W. Ma Dr Risa Ozaki Dr C.S. Cockram Dr H.K. Pang Dr I.M. Wong, Chinese University of Hong Kong (investigator-initiated study) GlaxoSmithKline Limited | Diabetes Mellitus | | | | |
| Completed | N/A | 210 | RoW | Rosiglitazone, Avandia, Placebo, crushed powder placebo | Centro de Investigacao em Saude de Manhica, University Health Network, Toronto, Barcelona Institute for Global Health | Malaria | 03/20 | 12/21 | | |
